Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novavax has entered into a collaborative research agreement with scientists at the University of Pittsburgh school of medicine to evaluate the efficacy of the company's virus-like particle influenza vaccines as well as Novasomes, a proprietary adjuvant.
Subscribe to our email newsletter
Under the new agreement, researchers from both companies will evaluate the full range of immunity elicited by virus-like particle (VLP) influenza vaccines developed at Novavax.
In addition, scientists will evaluate the use of Novasomes to augment and/or broaden the overall protective immune response elicited by vaccines, and to demonstrate the ability to lower the dose of antigen required to provide protection against influenza virus infection.
This preclinical data will supplement recent data published in collaboration with the Centers for Disease Control and Prevention showing Novavax influenza VLP vaccines can elicit a protective immune response.
“This approach has great potential for improving on the efficacy of currently available influenza vaccines, as well as for offering a practical solution to the need for rapid development and production of a vaccine for pandemic influenza,” said Dr Ted Ross, assistant professor of medicine with the University of Pittsburgh school of medicine.